Cutaneous adverse events and quality of life in outpatients receiving anticancer agents: results from an observational, cross-sectional study.
cutaneous adverse events
patient-reported outcomes
quality of life
targeted therapies
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
06
2020
revised:
13
07
2020
accepted:
13
07
2020
entrez:
22
8
2020
pubmed:
22
8
2020
medline:
22
8
2020
Statut:
epublish
Résumé
Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no extensive data on their impact on quality of life (QoL). Healthcare professionals should consider this issue in order to minimize its negative impact on QoL and improve patient outcomes. This study evaluates the impact of CAEs on QoL in outpatients receiving anticancer drugs and aims to determine the differences in QoL between conventional chemotherapy A total of 114 cancer patients with CAEs were included in this observational, cross-sectional study. Patient-reported outcomes instruments (Functional Assessment of Cancer Therapy - General, Dermatology Life Quality Index, and Skindex-16) were used. Mean scores in QoL indices were 65.3±13.4, 8.4±5, and 30.8±16.9 in Functional Assessment of Cancer Therapy - General, Dermatology Life Quality Index, and Skindex-16, respectively. The CAEs that had the greatest impact on dermatologic-related QoL were hand-foot skin reaction, rash, palmo-plantar erythrodysesthesia, and papulopustular eruption. No significant differences in QoL indices according to the type of treatment (conventional chemotherapy CAEs, and particularly hand-foot toxicities, rashes, and papulopustular eruptions, can have an impact on QoL in outpatients receiving anticancer drugs as evaluated with three different patient-reported outcomes instruments. No differences in QoL related to CAEs were observed between conventional chemotherapy and targeted therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Despite growing interest in cutaneous adverse events (CAEs) and their management in patients with cancer, they are often underreported and there are no extensive data on their impact on quality of life (QoL). Healthcare professionals should consider this issue in order to minimize its negative impact on QoL and improve patient outcomes. This study evaluates the impact of CAEs on QoL in outpatients receiving anticancer drugs and aims to determine the differences in QoL between conventional chemotherapy
METHODS
METHODS
A total of 114 cancer patients with CAEs were included in this observational, cross-sectional study. Patient-reported outcomes instruments (Functional Assessment of Cancer Therapy - General, Dermatology Life Quality Index, and Skindex-16) were used.
RESULTS
RESULTS
Mean scores in QoL indices were 65.3±13.4, 8.4±5, and 30.8±16.9 in Functional Assessment of Cancer Therapy - General, Dermatology Life Quality Index, and Skindex-16, respectively. The CAEs that had the greatest impact on dermatologic-related QoL were hand-foot skin reaction, rash, palmo-plantar erythrodysesthesia, and papulopustular eruption. No significant differences in QoL indices according to the type of treatment (conventional chemotherapy
CONCLUSIONS
CONCLUSIONS
CAEs, and particularly hand-foot toxicities, rashes, and papulopustular eruptions, can have an impact on QoL in outpatients receiving anticancer drugs as evaluated with three different patient-reported outcomes instruments. No differences in QoL related to CAEs were observed between conventional chemotherapy and targeted therapy.
Identifiants
pubmed: 32821263
doi: 10.7573/dic.2020-6-6
pii: dic-2020-6-6
pmc: PMC7413591
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2020 Suh Oh HJ, Flórez Menéndez A, Sacristán Santos V, Fernández Ribeiro F, Vilanova-Trillo L, Constenla Figueiras M, Pereiro Ferreiros M.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/07/dic.2020-6-6-COI.pdf
Références
Support Care Cancer. 2019 Sep;27(9):3421-3429
pubmed: 30661203
Support Care Cancer. 2012 Aug;20(8):1729-35
pubmed: 21922203
Support Care Cancer. 2018 Apr;26(4):1169-1179
pubmed: 29116406
J Cancer Educ. 2020 Aug;35(4):796-807
pubmed: 31054110
Support Care Cancer. 2017 Feb;25(2):651-660
pubmed: 27718067
Oncology. 2007;72(3-4):152-9
pubmed: 18160805
Am J Clin Dermatol. 2013 Aug;14(4):327-33
pubmed: 23625802
Dermatol Ther (Heidelb). 2019 Sep;9(3):505-510
pubmed: 31165365
Cureus. 2018 Mar 5;10(3):e2272
pubmed: 29736356
Support Care Cancer. 2010 Nov;18(11):1461-8
pubmed: 19956983
Am J Clin Dermatol. 2018 Nov;19(Suppl 1):31-39
pubmed: 30374901
Future Oncol. 2014 Oct;10(13):2003-5
pubmed: 25396773
Support Care Cancer. 2015 Aug;23(8):2231-44
pubmed: 25564221
Cancer Res Treat. 2018 Oct;50(4):1186-1193
pubmed: 29237254
Z Gastroenterol. 2013 Aug;51(8):733-9
pubmed: 23955138
Support Care Cancer. 2013 Apr;21(4):1033-41
pubmed: 23128934
J Cancer. 2019 Aug 27;10(20):4846-4851
pubmed: 31598155
Support Care Cancer. 2013 Jul;21(7):1919-26
pubmed: 23417565
Br J Dermatol. 2009 Sep;161(3):515-21
pubmed: 19466958
Drugs Context. 2018 Jul 17;7:212516
pubmed: 30038659
Clin Exp Dermatol. 1994 May;19(3):210-6
pubmed: 8033378
Br J Cancer. 2015 Aug 11;113(4):603-10
pubmed: 26203761
Ann Oncol. 2011 Oct;22(10):2179-90
pubmed: 21339384
Cancer. 2010 Aug 15;116(16):3916-23
pubmed: 20564072
J Eur Acad Dermatol Venereol. 2013 Jan;27(1):e53-9
pubmed: 22329482
Support Care Cancer. 2015 Dec;23(12):3645-52
pubmed: 26314706
Dermatol Clin. 2012 Apr;30(2):231-6, xiii
pubmed: 22284137
Health Qual Life Outcomes. 2003 Aug 20;1:32
pubmed: 12969512
Clin Transl Oncol. 2019 May;21(5):556-571
pubmed: 30284232
Psychooncology. 2008 Sep;17(9):891-900
pubmed: 18050153
J Clin Oncol. 1993 Mar;11(3):570-9
pubmed: 8445433
Crit Rev Oncol Hematol. 2016 May;101:158-68
pubmed: 26995080
J Clin Oncol. 2010 Mar 10;28(8):1351-7
pubmed: 20142600